Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 16 studies | 42% ± 23% | |
endothelial cell | 15 studies | 36% ± 14% | |
mast cell | 10 studies | 39% ± 15% | |
macrophage | 9 studies | 34% ± 14% | |
glutamatergic neuron | 7 studies | 31% ± 15% | |
microglial cell | 7 studies | 31% ± 10% | |
oligodendrocyte precursor cell | 7 studies | 41% ± 17% | |
astrocyte | 7 studies | 29% ± 14% | |
smooth muscle cell | 6 studies | 27% ± 12% | |
GABAergic neuron | 6 studies | 31% ± 15% | |
fibroblast | 6 studies | 31% ± 23% | |
cardiac muscle cell | 5 studies | 40% ± 14% | |
club cell | 5 studies | 32% ± 15% | |
type II pneumocyte | 5 studies | 25% ± 6% | |
myofibroblast cell | 4 studies | 33% ± 18% | |
myeloid cell | 4 studies | 24% ± 7% | |
endothelial cell of sinusoid | 3 studies | 34% ± 9% | |
hepatic stellate cell | 3 studies | 42% ± 12% | |
neuron | 3 studies | 18% ± 3% | |
endocardial cell | 3 studies | 49% ± 17% | |
endothelial cell of artery | 3 studies | 19% ± 4% | |
vein endothelial cell | 3 studies | 37% ± 26% | |
endothelial cell of vascular tree | 3 studies | 42% ± 15% | |
interneuron | 3 studies | 48% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 6287.42 | 653 / 653 | 93% | 63.69 | 560 / 605 |
prostate | 99% | 2464.38 | 243 / 245 | 84% | 8.82 | 423 / 502 |
breast | 100% | 2050.08 | 458 / 459 | 83% | 8.35 | 925 / 1118 |
adrenal gland | 100% | 4149.49 | 258 / 258 | 76% | 10.82 | 175 / 230 |
intestine | 97% | 2503.79 | 938 / 966 | 76% | 8.08 | 400 / 527 |
lung | 99% | 2005.91 | 575 / 578 | 73% | 9.27 | 848 / 1155 |
stomach | 92% | 2308.42 | 330 / 359 | 76% | 9.66 | 217 / 286 |
ovary | 95% | 1323.20 | 171 / 180 | 70% | 7.35 | 300 / 430 |
kidney | 81% | 911.06 | 72 / 89 | 67% | 8.57 | 606 / 901 |
bladder | 100% | 1866.81 | 21 / 21 | 47% | 4.32 | 236 / 504 |
esophagus | 91% | 3068.05 | 1319 / 1445 | 52% | 5.68 | 96 / 183 |
uterus | 99% | 3108.17 | 169 / 170 | 34% | 4.04 | 156 / 459 |
skin | 50% | 451.50 | 909 / 1809 | 79% | 12.33 | 373 / 472 |
liver | 81% | 1025.94 | 182 / 226 | 38% | 2.65 | 153 / 406 |
spleen | 100% | 4754.64 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5343.67 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1875.85 | 1197 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 2296.98 | 842 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 84% | 8.19 | 67 / 80 |
pancreas | 5% | 39.23 | 18 / 328 | 76% | 6.84 | 135 / 178 |
brain | 24% | 209.51 | 642 / 2642 | 48% | 2.68 | 338 / 705 |
tonsil | 0% | 0 | 0 / 0 | 38% | 2.08 | 17 / 45 |
lymph node | 0% | 0 | 0 / 0 | 28% | 1.47 | 8 / 29 |
muscle | 27% | 245.75 | 215 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 10.06 | 13 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045906 | Biological process | negative regulation of vasoconstriction |
GO_0030593 | Biological process | neutrophil chemotaxis |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0033627 | Biological process | cell adhesion mediated by integrin |
GO_0007155 | Biological process | cell adhesion |
GO_0098609 | Biological process | cell-cell adhesion |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0034679 | Cellular component | integrin alpha9-beta1 complex |
GO_0008305 | Cellular component | integrin complex |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0098640 | Molecular function | integrin binding involved in cell-matrix adhesion |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005178 | Molecular function | integrin binding |
Gene name | ITGA9 |
Protein name | Integrin alpha-9 (Integrin alpha-RLC) Alternative protein ITGA9 Integrin subunit alpha 9 |
Synonyms | |
Description | FUNCTION: Integrin alpha-9/beta-1 (ITGA9:ITGB1) is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. ITGA9:ITGB1 may play a crucial role in SVEP1/polydom-mediated myoblast cell adhesion (By similarity). Integrin ITGA9:ITGB1 represses PRKCA-mediated L-type voltage-gated channel Ca(2+) influx and ROCK-mediated calcium sensitivity in vascular smooth muscle cells via its interaction with SVEP1, thereby inhibiting vasocontraction . . |
Accessions | ENST00000707666.1 ENST00000422441.5 Q13797 H7C2L1 E9PDS3 ENST00000264741.10 L8E7C7 ENST00000411817.2 |